Financial News Conference on the Full Year 2022 Results

• Group sales increase 8.7 percent (Fx & portfolio adj.) to 50.739 billion euros
• EBITDA before special items rises 20.9 percent to 13.513 billion euros, largely driven by exceptionally strong performance at Crop Science
• Pharmaceuticals increases sales and earnings
• Consumer Health maintains dynamic growth
• Core earnings per share advance 22.0 percent to 7.94 euros
• Net income of 4.150 billion euros
• Free cash flow increases to 3.111 billion euros, net financial debt down to 31.809 billion euros
• Dividend of 2.40 euros per share proposed, up 20 percent
• New products post significant growth / Encouraging developments in the research pipeline
• Major progress made toward achieving long-term sustainability targets
• Outlook for 2023: Increase in sales (Fx & portfolio adj.); EBITDA before special items and core earnings per share below prior year as inflation remains high

MORE